
|Articles|October 14, 2004
Companies team up to market LHRH agonist
Watson Pharmaceuticals Inc. and Debiopharm S.A. have agreed to market triptorelin pamoate (Trelstar Depot, 3.75 mg, and Trelstar LA, 11.25 mg) within the United States and Canada.
Advertisement
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5










